期刊论文

中文

中国感染控制杂志

1671-9638

2022

21

10

1015-1018

10.12138/j.issn.1671-9638.20222956

2019B1515120003:广东省基础与应用基础研究基金 JCYJ20180508152244835:深圳市科技创新委员会基金 SZSM201811071:深圳市医疗卫生三名工程基金

本校为第一机构

人类免疫缺陷病毒(HIV)感染者存在不同程度的免疫缺陷,可能导致新型冠状病毒疫苗接种的有效性低于正常人群。HIV感染者应是新型冠状病毒疫苗加强针的优先群体,然而目前国内外尚未检索到HIV感染者接种新型冠状病毒灭活疫苗后使用腺病毒载体疫苗序贯加强免疫的报道。故本文报告1例HIV感染者,通过抗逆转录病毒治疗(ART)后,HIV得到良好抑制,CD4+T细胞计数正常,接种两剂新型冠状病毒灭活疫苗(国药集团中国生物北京生物制品研究所有限责任公司)后使用腺病毒载体疫苗(康希诺生物股份公司)序贯加强免疫,安全且具有高度免疫原性,为指导该人群新型冠状病毒疫苗接种提供参考依据。

People infected with human immunodeficiency virus(HIV) have different degrees of immune deficiency, which may lead to the lower vaccination effectiveness of SARS-CoV-2 vaccines than the normal population. HIV-infected person should be the priority group for booster shots of SARS-CoV-2 vaccines. However, at present, there are no reports of HIV-infected people receiving adenovirus vector vaccines for sequential booster immunization at home and abroad after receiving SARS-CoV-2 inactivated vaccines. Therefore, this paper reports a case of HIV-infected person whose HIV was well suppressed and CD4+...